Mirati Therapeutics Inc logo

MRTX - Mirati Therapeutics Inc Share Price

$116.99 -0.6  -0.5%

Last Trade - 02/07/20

Large Cap
Market Cap £4.09bn
Enterprise Value £3.53bn
Revenue £1.89m
Position in Universe 1082nd / 6344
Unlock MRTX Revenue
Relative Strength (%)
1m +15.8%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -11.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 12.9 3.34 4.05 17.8
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Mirati Therapeutics Inc revenues decreased 79% to $267K. Net loss increased from $40.9M to $86.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and develpment balancng value increase from $25.3M to $52.6M (expense), Stock-based Compensation in R&D increase from $5.2M to $11.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


MRTX Revenue Unlock MRTX Revenue

Net Income

MRTX Net Income Unlock MRTX Revenue

Normalised EPS

MRTX Normalised EPS Unlock MRTX Revenue

PE Ratio Range

MRTX PE Ratio Range Unlock MRTX Revenue

Dividend Yield Range

MRTX Dividend Yield Range Unlock MRTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MRTX EPS Forecasts Unlock MRTX Revenue
Profile Summary

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company develops product candidates to address the genetic and immunological promoters of cancer. Its clinical programs consist of two product candidates: MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor, and Sitravatinib, a multi-kinase inhibitor. Its KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit KRAS G12C mutations which are present in non-small cell lung cancer (NSCLC) adenocarcinoma patients, colorectal cancer (CRC) patients, pancreatic cancer patients, as well as several other difficult-to-treat cancers. Sitravatinib is a spectrum-selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated April 29, 2013
Public Since July 12, 2013
No. of Shareholders: 13
No. of Employees: 111
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 43,642,434
Free Float (0.0%)
Eligible for
MRTX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MRTX
Upcoming Events for MRTX
Monday 3rd August, 2020 Estimate
Q2 2020 Mirati Therapeutics Inc Earnings Release
Monday 2nd November, 2020 Estimate
Q3 2020 Mirati Therapeutics Inc Earnings Release
Frequently Asked Questions for Mirati Therapeutics Inc
What is the Mirati Therapeutics Inc share price?

As of 02/07/20, shares in Mirati Therapeutics Inc are trading at $116.99, giving the company a market capitalisation of £4.09bn. This share price information is delayed by 15 minutes.

How has the Mirati Therapeutics Inc share price performed this year?

Shares in Mirati Therapeutics Inc are currently trading at $116.99 and the price has moved by 6.74% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Mirati Therapeutics Inc price has moved by 1.98% over the past year.

What are the analyst and broker recommendations for Mirati Therapeutics Inc?

Of the analysts with advisory recommendations for Mirati Therapeutics Inc, there are there are currently 5 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Mirati Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Mirati Therapeutics Inc next release its financial results?

Mirati Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Mirati Therapeutics Inc dividend yield?

Mirati Therapeutics Inc does not currently pay a dividend.

Does Mirati Therapeutics Inc pay a dividend?

Mirati Therapeutics Inc does not currently pay a dividend.

When does Mirati Therapeutics Inc next pay dividends?

Mirati Therapeutics Inc does not currently pay a dividend.

How do I buy Mirati Therapeutics Inc shares?

To buy shares in Mirati Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Mirati Therapeutics Inc?

Shares in Mirati Therapeutics Inc are currently trading at $116.99, giving the company a market capitalisation of £4.09bn.

Where are Mirati Therapeutics Inc shares listed? Where are Mirati Therapeutics Inc shares listed?

Here are the trading details for Mirati Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: MRTX
What kind of share is Mirati Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Mirati Therapeutics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Mirati Therapeutics Inc share price forecast 2020?

Shares in Mirati Therapeutics Inc are currently priced at $116.99. At that level they are trading at 0.92% discount to the analyst consensus target price of 0.00.

Analysts covering Mirati Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -8.577 for the next financial year.

How can I tell whether the Mirati Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mirati Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 7.19%. At the current price of $116.99, shares in Mirati Therapeutics Inc are trading at 24% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Mirati Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Mirati Therapeutics Inc.

Who are the key directors of Mirati Therapeutics Inc?

Mirati Therapeutics Inc's management team is headed by:

Henry Fuchs - IND
Charles Baum - PRE
James Christensen - EVP
Michael Grey - IND
Bruce Carter - IND
Aaron Davis - IND
Faheem Hasnain - CHM
Julie Cherrington - IND
Daniel Faga - COO
Benjamin Hickey - EVP
Joseph Leveque - OTH
Who are the major shareholders of Mirati Therapeutics Inc?

Here are the top five shareholders of Mirati Therapeutics Inc based on the size of their shareholding:

Avoro Capital Advisors LLC Investment Advisor/Hedge Fund
Percentage owned: 9.42% (4.11m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.8% (3.40m shares)
Perceptive Advisors LLC Private Equity
Percentage owned: 7.61% (3.32m shares)
Braslyn, Ltd. Corporation
Percentage owned: 7.19% (3.14m shares)
Aviva Holdings Ltd. Investment Advisor
Percentage owned: 7.19% (3.14m shares)
Similar to MRTX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.